热门资讯> 正文
Market-Moving News for December 8th
2025-12-08 20:34
FULC: 66% | Fulcrum Therapeutics Announced Saturday, Initial Results From 20 mg Dose Cohort Of The Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease; Clear Dose-response Observed, With Robust, Clinically Meaningful Fetal Hemoglobin Induction At Week 6 Timepoint
KYMR: 24% | Kymera Therapeutics shares are trading higher after the company announced it will share results from the BroADen Phase 1b clinical trial evaluating KT-621, on Monday, December 8, 2025.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
